IRIDEX Corporation (NASDAQ: IRIX) and BIOLASE (NASDAQ:BLTI) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Valuation and Earnings

This table compares IRIDEX Corporation and BIOLASE’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
IRIDEX Corporation $42.80 million 2.53 -$5.81 million ($1.51) -6.21

BIOLASE has higher revenue, but lower earnings than IRIDEX Corporation.

Insider and Institutional Ownership

47.5% of IRIDEX Corporation shares are owned by institutional investors. 5.0% of IRIDEX Corporation shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares IRIDEX Corporation and BIOLASE’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IRIDEX Corporation -37.62% -16.87% -13.86%
BIOLASE -34.01% -151.86% -43.37%

Analyst Ratings

This is a breakdown of recent ratings for IRIDEX Corporation and BIOLASE, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IRIDEX Corporation 0 0 1 0 3.00
BIOLASE 0 0 0 0 N/A

IRIDEX Corporation currently has a consensus price target of $20.00, suggesting a potential upside of 113.45%. Given IRIDEX Corporation’s higher possible upside, research analysts plainly believe IRIDEX Corporation is more favorable than BIOLASE.


IRIDEX Corporation beats BIOLASE on 7 of the 8 factors compared between the two stocks.

IRIDEX Corporation Company Profile

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

BIOLASE Company Profile

BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

Receive News & Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.